29 C
Vientiane
Saturday, July 19, 2025
spot_img
Home Blog Page 134

Connect to Care Global Launches to Drive Post-Aid Development Across Global South

Singapore-based consultancy offers political, digital, business-driven and South–South solutions to overcome reduction in Global North aid budgets.

SINGAPORE, June 3, 2025 /PRNewswire/ — Connect to Care Global (CTCG), a Singapore-based development organisation, officially launched today to help international agencies and regional partners across the Global South navigate a rapidly changing aid landscape. As the Global North reduces its traditional aid commitments, a post-aid world is emerging that demands smarter, faster, and more locally grounded solutions.

“It’s a critical time for all of us in the Global South as we grapple with a multitude of problems in the face of declining Global North aid budgets,” said Chandita Samaranayake, Founder and Director of CTCG. “Connect to Care Global is both a comprehensive response to this challenge and an opportunity to build a more resilient development sector across the Global South.”

Backed by a regional network of experienced consultants based across South and Southeast Asia, CTCG brings together deep local knowledge with cross-sector expertise in technology, strategic communications, and non-profit operations. The team includes former diplomats, advisors to governments, private sector and CSO leaders and has delivered projects in every part of Asia, offering a unique ability to bridge global strategic thinking with local execution.

While officially launching today, CTCG has been delivering for the past 12 months, including nutrition, water resource management and recycling projects in Sri Lanka, Indonesia and Rwanda. 

CTCG’s approach is built upon three core pillars:

  • Think and acting politically – by aligning with local power structures and governance dynamics
  • Adopting digital solutions – leveraging tech to scale impact across health, education, agriculture, governance, and finance
  • Building South–South cooperation – promoting peer learning, context-aware solutions, and regional capacity-building

The organisation’s fundamental approach relies on unlocking the power of local and regional talent. Designing projects that include local private sector stakeholders and align with government priorities while taking into account the priorities and needs of development sector partners.  

Now open for partnerships, Connect To Care Global invites development agencies, multilateral institutions, private sector organizations and foundations to collaborate on politically smart, digitally enabled, and regionally grounded programs.

For more information, please visit the CTCG website.

– END –

About CTCG

Connect to Care Global is a mission-driven consulting and implementation partner helping development actors accelerate sustainable impact across South and Southeast Asia. Headquartered in Singapore, CTCG combines regional expertise with global insights to support the next generation of development programs.

 

Self Storage Awards Asia Gala Dinner announces winners at Self Storage Expo Asia 2025

HONG KONG, June 3, 2025 /PRNewswire/ — The Self Storage Association Asia announces the Self Storage Association Awards Asia 2025 winners in Tokyo.

The Awards recognise Asia-wide and local excellence in self storage in customer service, the use of technology and other key industry metrics. Industry leaders across Asia are raising safety standards, customer service and good governance.

Consumers, investors and governments can look to the award winners for the gold standard in self storage in Asia. Self storage is proving a vital industry for empowering small and large businesses to grow through flexible use of space for modern economies.

The full list of finalists and  details of the entries are at the Awards website at https://selfstorageasia.org/award-winners-2025.

Multi-Site Operator Store of the Year recognises the best self storage site in Asia operated by a large company.

Winner Asia & Singapore: Work+Store

Regional winners:

  • Hong Kong SAR: RedBox Storage
  • The Philippines: Loc&Stor 24/7 Sucat

Independent Store of the Year recognises the best self storage site in Asia operated by a smaller company.

Independent Store of the Year & La Réunion Winner: IZIBOX

Regional winners:

  • The Philippines: INSTORAGE BY CLAIRMONT
  • Jordan: Easy Storage Jordan

Valet Storage of the Year recognises the best valet storage company in Asia providing door-to-door service.

Winner Asia and Hong Kong: Valet Stored!

Manager of the Year recognises an on-site manager who has outperformed their peers across Asia.

Winner Asia and Japan:  Quraz – Rumiko Uchida

Regional winners:

  • Singapore: Lock+Store – Soh Xun Ling
  • Hong Kong SAR: The Store House – Walter Wu

The Environmental, Social, and Governance Initiative Award (ESG Award) recognises excellence in initiatives advancing ESG goals.

Winner Asia and Japan: Arealink Co.,Ltd / Hello Storage

Regional winners:

  • Singapore: StorHub Self Storage
  • The Philippines: INSTORAGE BY CLAIRMONT
  • Dubai: The Box Self Storage
  • La Réunion: IZIBOX
  • Hong Kong SAR: Storefriendly

The Technology & Innovation Award recognises the implementation of technology in operations or customer service above and beyond industry standards.

Winner Asia and Thailand: LEO Self Storage

Regional winners:

  • Vietnam: MyStorage Vietnam
  • Hong Kong SAR: Storefriendly

The Creative & Effective Marketing Award recognises novel thinking that delivers results in driving sales through marketing.

Winner Asia and Singapore:  Work+Store

Regional winner:

  • La Réunion: IZIBOX

The Customer Experience Satisfaction Award recognises operators who have demonstrated outstanding service levels, customer care, and user experience, setting new standards in customer satisfaction.

Winner Asia and Thailand: i-Store Self Storage

Regional winners:

  • The Philippines: INSTORAGE BY CLAIRMONT
  • Hong Kong SAR: RedBox Storage

About the Self Storage Association Asia

The SSAA is the industry body representing and serving the self storage industry in Asia from Japan to Jordan. Its members comprise the best of class self storage operators, their suppliers and investors. The SSAA provides training, advocacy, intelligence, market reports and a networking platform to help operators to continue to improve and grow.

Investbanq Reflects on the Road Ahead After a Successful Meet the Drapers Finale

SINGAPORE, June 3, 2025 /PRNewswire/ — As the season seven finale of the global startup reality show Meet the Drapers aired, Singapore-based fintech startup Investbanq took a moment to reflect on what the experience meant—not just as a recognition of its product, but as a turning point in its journey.

One of seven finalists to be named winners of the competition, Investbanq presented its next-generation AI-powered wealth operating system built for financial institutions. The pitch stood out for its focus on enabling the next generation of wealth managers and family offices with scalable, intelligent financial tools.

During the finale, Silicon Valley investor Tim Draper encouraged the team to explore a new dimension—education—as part of their broader mission. As the episode closed, Draper extended his hand to CEO Oz Zhiyenkul, offering a mysterious, yet promising remark: “Soon to be congratulations.”

“Initially, I was disappointed we didn’t walk away with a definitive deal,” said Zhiyenkul. “But the production team shared that outcomes like ours are rare—and often signal something deeper could be in the works. That helped reframe it. For us, it was not just a pitch, but a catalyst.”

This milestone builds on Investbanq’s growing international momentum, which includes sustained revenue growth, institutional interest, and a recent industry award for Best WealthTech Solution – Artificial Intelligence from Global Private Banker. Inspired by Draper’s feedback, Investbanq has begun developing an AI-driven financial education module to support the next generation of investors—further reinforcing its mission of inclusion and accessibility in wealth management.

“Looking back, Meet the Drapers wasn’t just a stage—it was a mirror. It reflected where we are, and more importantly, where we’re headed,” said Zhiyenkul.

About Investbanq

Co-founded by Kazakhstani entrepreneurs Oz (Olzhas) Zhiyenkul and Tk (Talgat) Kantayev, Singapore-based Investbanq aims to redefine the future of wealth management by building a more inclusive, modular, and AI-native financial infrastructure. Its platform offers a full-stack digital infrastructure for banks, asset managers, and family offices, digitizing onboarding, CRM, portfolio management, compliance, and reporting.

AI is central to Investbanq’s architecture, not a bolt-on. Features like the Advisor Co-Pilot and LLM integrations deliver automation, personalization, and real-time insights—transforming how advisors serve clients.

Investbanq is headquartered in Singapore, with offices in Kazakhstan and the UAE, and holds regulatory approvals from MAS, AIFC, and DFSA (IPA).

About Meet the Drapers

Meet the Drapers is a premier startup reality show where founders pitch their ventures to the legendary Draper family, a Silicon Valley dynasty known for backing early-stage game-changers. Finalists compete for funding, exposure, and access to a worldwide investor network.

Watch Investbanq’s finale pitch: https://drapertv.com/titles/6357/finale-meet-the-drapers-season-07

 

 

INCUBASE Studio Brings Unmissable Anime Experiences Across Asia: From Crayon Shinchan to Beloved BL Hits

HONG KONG, June 3, 2025 /PRNewswire/ — INCUBASE Studio is bringing anime to life across Asia with a wave of immersive experiences, including the newly launched “Crayon Shinchan: Space & Time Adventure Interactive Exhibition” and the popular “Delicious in Dungeon Exploration Exhibition” in Hong Kong. As a leading curator of anime exhibitions, the Studio continues to introduce beloved IPs to fans through dynamic storytelling and regional-first showcases.

INCUBASE Studio’s latest original curation “Crayon Shinchan: Space & Time Adventure Interactive Exhibition” debuted in Hong Kong and is open now until August 31.
INCUBASE Studio’s latest original curation “Crayon Shinchan: Space & Time Adventure Interactive Exhibition” debuted in Hong Kong and is open now until August 31.

New Shinchan Exhibition Opens in Hong Kong as Part of Asia Tour

The brand-new and highly anticipated “Crayon Shinchan: Space & Time Adventure Interactive Exhibition” is INCUBASE Studio‘s latest original curation, now officially open at Kai Tak Mall through August 31. Making its Hong Kong debut as part of an Asia tour, the exhibition is also the first interactive Crayon Shinchan showcase in the city and the first large-scale themed exhibition hosted at the prominent Kai Tak Mall. Drawing from the manga, anime and movies, the exhibition spans 5 themed zones and 9 exhibition areas filled with interactive games and mobile app integrations, offering a whimsical, time-traveling adventure for visitors of all ages.

INCUBASE Arena’s themed exhibits and pop-up stores

Meanwhile, the anime culture hub INCUBASE Arena brought the “Delicious in Dungeon Exploration Exhibition” to Hong Kong for the first time, featuring detailed recreations of iconic scenes, exclusive photo zones, and a special appearance by voice actor Asuna Tomari at the opening ceremony. The exhibition also includes a showcase of art replica by author Ryoko Kui, adding artistic depth to the experience. This marks the first project following INCUBASE Studio‘s strategic partnership with K11 Concepts Management, leveraging the K11 Experience ticketing platform to reach a broader audience.

Beyond large-scale exhibitions, INCUBASE Arena curates a wide range of pop-up stores and thematic events. Recent launches include the “Twittering Birds Never Fly” Pop-up Store, featuring art replicas, exclusive merchandise and photo spots from the globally loved BL manga, as well as “The Tower of God: The Workshop Battle” Pop-up Store bringing scene and costume displays and merchandise to fans. The “Sweetscape Art Exhibition” will take place during June 7 – 15, celebrating the creative work of 27 Hong Kong illustrators while supporting the local creative community.

INCUBASE Experiences beyond Hong Kong

INCUBASE Studio‘s footprint continues to grow across Asia. In Kuala Lumpur, the “Cardcaptor Sakura Exhibition: The Enchanted Museum” became the second major exhibit at INCUBASE Arena Malaysia, while the first-ever One Piece Asia Hunt has launched at SplashMania WaterPark, offering fans an immersive, real-world treasure hunt adventure.

Following successful runs in Hong Kong and Kuala Lumpur, the “Kamen Rider 50th Anniversary Exhibition” has now opened in Bangkok, alongside the massive “100% DORAEMON & FRIENDS Tour Thailand”, one of the largest Doraemon showcases in the world.

The acclaimed “One Piece: The Great Era of Piracy Asia Tour”, the first curation by INCUBASE Studio, has reached its 7th stop in Shanghai, Mainland China, and is set to continue to Pingtung in southern Taiwan from June 21.

“The Chainsaw Man Animation Exhibition” is currently on its Asia tour in Taipei following its debut in Hong Kong earlier this year. Its next stop is set for Seoul, South Korea this July, where it will be joined by the Tokyo Revengers and Oshi no Ko exhibitions, both concluding in June.

Promote anime culture through exhibition experiences

“As a curator, I believe that hosting diverse anime exhibitions not only celebrates the incredible works but also plays a vital role in promoting anime culture. We aim to connect with fans across Asia and beyond, creating immersive spaces where everyone can come together to share and celebrate their passion,” shared Sion Yip, Founder and CEO of INCUBASE Studio.

Through compelling curations and strategic collaborations, INCUBASE Studio is redefining anime experiences for fans worldwide, connecting generations through storytelling, design, and a shared love for anime culture.

About INCUBASE Studio

INCUBASE Studio curates diverse IP-themed exhibition experiences that celebrate and connect fandoms worldwide. The Studio brings stories to life by blending captivating content with engaging installations and interactive devices. Since its establishment in Hong Kong in 2021, INCUBASE Studio has been committed to realising and promoting Touring Experiences across Asia, pushing the boundaries of physical venues and experiences.

In 2024, INCUBASE Studio established INCUBASE Arena in Hong Kong and Malaysia as hubs for Japanese anime culture and entertainment experiences, continuously hosting a variety of popular anime IP exhibitions and related events to build a vibrant community for anime fans in both regions and the surrounding areas.

www.incubasestudio.com 

 

First Phosphate Closes Final Tranche of Oversubscribed Private Placement


Saguenay, Quebec – Newsfile Corp. – June 2, 2025 – First Phosphate Corp. (CSE: PHOS) (OTCQB: FRSPF) (FSE: KD0) (“First Phosphate” or the “Company“) is pleased to announce that it has closed the second and final tranche of its non-brokered private placement financing (the “Offering“), as further described in the Company’s news releases dated May 9, 2025 and May 28, 2025.

As part of both tranches of the Offering, the Company raised a total of $3,517,519 through the issuance of 7,275,309 Flow-Through Shares at a price of $0.35 for gross proceeds of $2,773,858, and 2,124,747 Hard Dollar Units at a price of $0.35, comprised of 2,124,747 Common Shares and 1,062,373 Warrants, for gross proceeds of $743,661.

Together with this Offering, the Company has raised to date a total of approximately $23.8 million in 7 management-led non-brokered private-placement financings since June 2022.

Under the final tranche of the Offering, the Company raised a total of $1,126,365 through the issuance of 2,883,429 Flow-Through Shares for gross proceeds of $1,009,200, and 334,757 Hard Dollar Units, comprised of 334,757 Common Shares and 167,378 Warrants, for gross proceeds of $117,165.

In total, in connection with the Offering, the Company paid $800 in cash finder’s fees, issued 471,152 Compensation Shares and advisory shares at a price of $0.35 per common share, and issued 444,867 Compensation Warrants, exercisable at a price of $0.50 per common share of the Company, until December 31, 2025, subject to an Accelerated Expiry Date. All securities issued under the Offering are subject to a four-month and one day statutory hold period in accordance with applicable securities laws. The Company intends to use the proceeds from the Offering as disclosed in the Company’s press release dated May 9, 2025. Capitalized terms used in this news release and not defined herein have the meanings given to them in the Company’s news release dated May 9, 2025.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Completion of the Offering is subject to certain conditions including, but not limited to, the receipt of all necessary approvals. There can be no assurance that any further securities will be sold under Offering.

About First Phosphate Corp.
First Phosphate (CSE: PHOS) (OTCQB: FRSPF) (FSE: KD0) is a mineral development company dedicated to producing high-purity phosphate for the LFP battery industry. The Company is committed to sustainable extraction and purification with a low anticipated carbon footprint. Its vertically integrated model connects phosphate mining directly into the supply chains of North American battery producers. First Phosphate’s flagship project, the Bégin-Lamarche Property in Saguenay-Lac-Saint-Jean, Quebec, contains rare igneous anorthosite rock that yields high-purity phosphate with minimal impurities.

For additional information, please contact:
Bennett Kurtz
Chief Financial Officer
bennett@firstphosphate.com
Tel: +1 (416) 200-0657

Investor Relations: investor@firstphosphate.com
Media Relations: media@firstphosphate.com
Website: www.FirstPhosphate.com

Follow First Phosphate:
X : https://x.com/FirstPhosphate
LinkedIn: https://www.linkedin.com/company/first-phosphate

-30-

Forward-Looking Information and Cautionary Statements
This news release contains certain statements and information that may be considered “forward-looking statements” and “forward-looking information” within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking statements and forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved” and other similar expressions. In addition, statements in this news release that are not historical facts are forward-looking statements, including, among other things: the Company’s planned exploration and production activities; the properties and composition of any extracted phosphate; the Company’s plans for vertical integration into North American battery supply chains; and the receipt of all necessary approvals.

These statements and other forward-looking information are based on assumptions and estimates that the Company believes are appropriate and reasonable in the circumstances, which may prove to be incorrect, include, but are not limited to, the various assumptions set forth herein and in the Company’s public disclosure record including the short form base prospectus dated June 5, 2024, and the receipt of all necessary approvals.

There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. There can be no assurance that any opportunity will be successful, commercially viable, completed on time or on budget, or will generate any meaningful revenues, savings or earnings, as the case may be, for the Company. In addition, the Company will incur costs in pursuing any particular opportunity, which may be significant. These factors and assumptions are not intended to represent a complete list of the factors and assumptions that could affect the Company and, though they should be considered carefully, should be considered in conjunction with the risk factors described in the Company’s other documents filed with the Canadian and United States securities authorities, including without limitation the “Risk Factors” section of the Company’s Management Discussion and Analysis dated January 29, 2025 and Annual Report on 20-F dated July 8, 2024, which are available on SEDAR+ at www.sedarplus.ca. Although the Company has attempted to identify factors that would cause actual actions, events or results to differ materially from those disclosed in the forward-looking information or information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

The issuer is solely responsible for the content of this announcement.

Translators’ Voices: China shares technological achievements with the world for mutual benefit

BEIJING, June 3, 2025 /PRNewswire/ — May 30, 2025 marks the ninth National Science and Technology Workers Day. In the early morning of the previous day, Tianwen-2, the country’s first asteroid probe and sampling mission, soared into the sky, carrying with it humanity’s aspirations for the stars and the universe.

The nation will thrive when science and technology develops, and the country will be strong when science and technology becomes advanced. The book series of Xi Jinping: The Governance of China contains multiple important speeches on science and technology. In the article “Strive for Greater Strength and Self-Reliance in Science and Technology” included in the fourth volume of the book series, President Xi emphasized that science and technology respond to the call of the times and have a global impact; they belong to all of humanity. “We should participate to the full in global science and technology governance, contribute Chinese wisdom, and shape a philosophy of technology for good purposes, so that science and technology better serve human wellbeing, and enable China’s science and technology industry to contribute more to building a global community of shared future!”

In the fifth installment of the “Decoding the Book of Xi Jinping: The Governance of China” series, the Global Times focuses on the theme of “practicing the philosophy of technology for good purposes and polishing China’s new name card in scientific and technological innovation.” We continue to invite Chinese and international scholars, translators of the work, practitioners of its concepts, and overseas readers to share their insights, understandings and reflection on China’s philosophy of science and technology development and international cooperation.

In the fifth article of the “Translator’s Voices” column, Global Times (GT) reporter Ma Ruiqian talked to Tomokazu Ueno (Ueno), a Japanese expert at the Center for Asia-Pacific of China International Communications Group. Ueno was involved in the translation and editorial work for the Japanese editions of Xi Jinping: The Governance of China.

GT: China’s scientific and technological development over the past decades – especially in recent years – has drawn global attention. Some say that technological innovation has become a “new calling card” of China. Do you agree with this view? You’ve mentioned that the application of technology in everyday life has brought greater convenience to ordinary people. What experiences from your work and life in China have led you to feel this way?

Ueno: I fully agree with this view – technology has indeed become one of the symbols of China’s modernization. What impresses me most is how quickly technological applications are integrated into society and made practical. For example, when I first arrived in Beijing and rented an apartment through a real estate agency, I was amazed to find that the entire rental process could be completed through a smartphone app. At places like train stations and hospitals, online systems are also widely used, so there’s almost no need to wait in long lines like before.

What also shocked me was that not only young people, but even most elderly people can use smartphones proficiently. Nearly all purchases can be made via mobile payment, which brings great convenience to daily life. To be honest, after getting used to this lifestyle, every time I go back to Japan to visit family, I find it a bit troublesome to carry cash, a wallet, transportation cards and various point cards again.

GT: Yes, technological innovation not only facilitates the daily lives of ordinary people in China but also serves as a key driver for the high-quality development of related industries. In May, during an inspection tour in Central China’s Henan Province, President Xi, emphasized the importance of “technological empowerment” and “independent innovation.” You have witnessed firsthand how technology is empowering the logistics and agricultural sectors in Xinjiang. How do you view the significance of technological empowerment for the development of Chinese industries?

Ueno: When I was interviewing in the Xinjiang Uygur Autonomous Region, I was deeply impressed by the high level of mechanization in local agriculture. Not only are large tractors used during the harvest, but new agricultural technologies are also widely applied in planting methods, field management, product transportation, environmental protection and water conservation. Agricultural technology is widely applied across the board. I realized that in China, even agriculture – one of the most traditional industries – is actively embracing high-tech tools. This not only significantly increases farmers’ incomes but also strongly boosts local development.

This example shows that China clearly understands that in order to improve people’s livelihoods and help them lead better lives, it is essential to revitalize local industries and promote sustainable development in different regions. The key to achieving this is technological innovation. In China, progress in high technology is closely tied to improvements in living standards.

GT: The fourth volume of Xi Jinping: The Governance of China includes an article titled “Strive for Greater Strength and Self-Reliance in Science and Technology.” In the article, President Xi points out that “science and technology respond to the call of the times and have a global impact; they belong to all of humanity.” How do you understand the “global impact” of science and technology as mentioned by President Xi?

Ueno: The way I understand this is that science and technology know no borders – they can bring benefits to the entire world and help address global challenges. China has consistently emphasized contributing to the world through “Chinese wisdom” and “Chinese solutions,” and it has put this philosophy into practice. Chinese technologies and their applications have already played a role in many areas around the world – including environmental protection, poverty alleviation, industrial development and improvements in people’s livelihoods – achieving notable results.

There is no doubt that the path China is taking – one that respects the idea that science and technology respond to the call of the times and have a global impact – is the right path for today’s world.

GT: At the meeting with China’s sci-tech workers in 2024, President Xi said that Chinese modernization should be supported by sci-tech modernization. You will soon host the fifth season of Finding Answers in China, which also focuses on Chinese modernization. How do you understand the idea that science and technology “respond to the call of the times”? How do you think sci-tech modernization has contributed to the success of Chinese modernization?

Ueno: I believe that “responding to the call of the times” means that science and technology reflect the defining features of a given era and serve as a driving force that propels modern society forward.

One of my strongest impressions regarding this idea came during an interview I conducted for Finding Answers in China, when I spoke with a Japanese entrepreneur engaged in water treatment projects in China. He remarked that while some countries still only prioritize development at the expense of environmental protection – and some leaders even continue to question the reality of global warming – China, along with the global mainstream, has shifted toward emphasizing environmental.

Environmental protection technology is one of the most representative fields that respond to the call of the times, and I’ve personally witnessed how China has significantly increased its attention and investment in this area over the past decade. This perfectly embodies the principle of “green development” emphasized in Chinese modernization – using technology to resolve the tension between development and the environment, and striving for harmonious coexistence between humanity and nature.

GT: In his article “Strive for Greater Strength and Self-Reliance in Science and Technology,” President Xi stated, “We should participate to the full in global science and technology governance, contribute Chinese wisdom, and shape a philosophy of technology for good purposes.” In your view, what is the significance of China’s philosophy and practice of “technology for good purposes” for the international community, especially for the vast number of Global South countries?

Ueno: Science and technology have a dual nature – depending on how they are used, they can either advance human development or cause harm. The philosophy of “technology for good purposes” is essentially a profound proposition about how a country should make good use of its scientific and technological resources within the international community.

From a global perspective, developing countries with relatively weak scientific foundations have an even greater need for science and technology to achieve development. China not only makes active calls, but also takes concrete actions to share its technological achievements with these countries, aiming to bring benefits to all of humanity. This approach emphasizes not monopoly over technology and wealth, but sharing and mutual benefit. Such a philosophy helps narrow the development gap between nations and thereby promotes global stability and prosperity.

GT: What are your expectations for China’s further participation in global science and technology governance and its growing role in the future of technological development? In Japan, there are sometimes mixed views regarding China’s pursuit of self-reliance and its technological rise. What is your opinion on this? And what message would you like to share about bilateral cooperation in the field of science and technology?

Ueno: In interviews with Japanese companies operating in China, I’ve noticed that many of them are now not only setting up manufacturing bases in China but also relocating their research and development centers here. I believe there is already a solid foundation and a wealth of achievements in ChinaJapan cooperation in science and technology, with considerable potential for further growth. Looking ahead, I hope both sides can continue to expand collaboration based on their respective strengths.

However, especially since the beginning of this year, there seems to be a growing headwind against cooperation. Science, by its nature, is a pursuit of rationality. It is regrettable when irrational political interference obstructs scientific collaboration. China has not compromised under such pressure and continues to uphold the principle of win-win cooperation. I can sense that China is playing an increasingly important role in guiding the world toward the right path.

welzo Establishes New Subsidiary in Singapore to Accelerate Expansion into Southeast Asia

FUKUOKA, Japan, June 3, 2025 /PRNewswire/ — welzo Inc., an innovation-driven company in the agri-horticultural sector (Head Office: Hakata-ku, Fukuoka City, Fukuoka Prefecture; President and CEO: Yoshifumi Kanao), has established a wholly owned subsidiary, welzo Singapore PTE. LTD., in Singapore as of June 2, 2025. This move marks a significant step in accelerating its  expansion into the Southeast Asian market and strengthening its global business development.

Background and Purpose

welzo has been actively expanding its business both domestically and internationally. Considering the rapid growth and diverse opportunities in the Southeast Asian market, weve strategically chosen Singapore as its regional base. With its excellent business environment and international connectivity, Singapore serves as a key hub for accessing ASEAN countries.

Business Activities of the New Office

Its Singapore office will serve as a central hub for marketing and business development across Southeast Asia, focusing on the following key areas:

– Development and Execution of Marketing Strategies for Southeast Asia
  welzo will implement promotional initiatives tailored to the market characteristics and consumer trends of each country, aiming to enhance brand recognition and expand sales channels. The company will also actively participate in trade shows and collaborate with local partners on marketing efforts.

– Import and Export of Agricultural Products, Feed Ingredients, and Pet Supplies
  through partnerships with local agricultural and pet-related businesses, we will establish a responsive supply system.  The company will promote the export of high-quality, safe Japanese products and the import of raw materials that meet local needs.

– Building Local Partnerships and Optimizing the Supply Chain
  Its Singapore office will centrally manage logistics, customs, and quality control operations to establish a more efficient and flexible supply chain.

– Recruitment and Development of Local Talent
  we will actively recruit skilled local professionals to promote regionally rooted business operations.  The company aim to provide multilingual and culturally sensitive services.

This new office will serve as a core base for its Southeast Asian operations and is expected to play a pivotal role in future regional expansion and global business growth. By leveraging its  Singapore office, we will strengthen its  ability to deliver value tailored to local needs and foster co-creation with local communities.

The welzo Group remains committed to contributing to a sustainable global society by promoting environmentally and socially responsible business practices. Through collaboration and co-creation with diverse partners across regions and industries, we aim to deliver new value on a global scale.

Yoshifumi Kanao, President & CEO of welzo Inc.
Yoshifumi Kanao, President & CEO of welzo Inc.

Comment from Yoshifumi Kanao, President & CEO of welzo Inc.

“Singapore is not just a gateway to Southeast Asia—it’s a global hub where innovation and agriculture can converge. With this new subsidiary, we aim to deliver high-quality Japanese products to local markets while building sustainable partnerships rooted in mutual growth. This marks a crucial step in our journey toward global co-creation.”

Overview of the New Subsidiary

Company Name: welzo Singapore PTE. LTD.
Address: 80 Robinson Road #10-01A Singapore 068898
Date of Establishment: June 2, 2025
Main Business Activities: marketing in Southeast Asia; import/export of agricultural products, feed ingredients, and pet supplies

Company Overview: welzo Inc.

welzo Inc. is a specialized trading company that provides products and services to enrich lives and promote a sustainable society through food and agriculture. Formerly known as Nichiryu Nagase, the company celebrated its  101st anniversary in 2022 and changed the company name to welzo Inc. on January 1, 2023. With 24 offices across Japan, welzo primarily operates in the B2B sector, handling agricultural materials, home gardening supplies, and feed ingredients. The company actively collaborate with internal and external partners and leverages IT and AI technologies to address pressing societal challenges in Japan.

Head Office: 1-14-3 Hakata Ekihigashi, Hakata-ku, Fukuoka City, Fukuoka Prefecture
President and CEO: Yoshifumi Kanao
Established: August 1952 (Founded August 1921)
Capital: 470 million yen
Sales: 50.137 billion yen (FY ending December 2024)
Business: Specialized trading company handling agricultural materials, home gardening supplies, and feed ingredients

2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors

SAN FRANCISCO and SUZHOU, China, June 3, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, updated the clinical data of IBI354 (HER2 monoclonal antibody-camptothecin derivative conjugate) in advanced solid tumors at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

IBI354 has demonstrated promising anti-tumor efficacy and favorable safety profiles across multiple solid tumors. It not only holds potential to deliver a new generation of ADC therapies characterized by “high potency and low-toxicity” for tumor types such as ovarian cancer and breast cancer, but also validates the advantages of Innovent’s ADC technology platform. The results of IBI354 lays the foundation for the subsequent development of Innovent’s next-generation of bispecific ADCs and dual-payload ADCs, marking a milestone in Innovent’s next-generation “IO+ADC” oncology development strategy.

The data presented is from a Phase 1/2 clinical study (NCT05636215) aimed at evaluating the safety, tolerability, and preliminary efficacy of IBI354 in participants with advanced solid tumors. As of March 24, 2025, a total of 368 participants with advanced solid tumors were enrolled and received different doses of IBI354 monotherapy, the median follow-up duration was 11.5 months (range: 0.7-19.6), the median treatment duration was 27.0 weeks (range: 3.1-81.3) and 74 (20.1%) pts were still on treatment. The tumor types including 178 with breast cancer, 92 with ovarian cancer, 38 with colorectal cancer, and 60 with other tumors.

IBI354 monotherapy demonstrated excellent safety profile

  • The dosage was escalated to 18mg/kg, with no DLT events observed.
  • The most common treatment-related adverse events (TRAEs) were anemia, nausea, and white blood cell count decreased. The incidence of interstitial lung disease (ILD) was only 1.9%, all were grade 1-2.
  • Overall, 27.4% of patients experienced TRAEs ≥ grade 3, 17.7% experienced TRAEs leading to dose interruption, 2.7% experienced TRAEs leading to dose reduction and 1.6% experienced TRAEs leading to discontinuation, with no TRAEs leading to death.

IBI354 monotherapy showed promising efficacy signals in multiple tumor types

  • In HER2-positive breast cancer cohort (n= 88, treated at 6~15mg/kg, the median prior treatment lines was 4), the confirmed objective response rate (ORR) and the disease control rate (DCR) were 59.1% and 90.9%, respectively. In 9 mg/kg Q3W subgroup (n=29), the ORR and the DCR were 72.4% and 89.7%, respectively. The median progression-free survival (PFS) was 14.1 months (95% CI: 8.3-not calculable [NC]) with events of 48.3%. The median overall survival (OS) was immature with events of 3.4%.
  • In ovarian cancer cohort (n=92, treated at 2~12mg/kg, the median prior treatment lines was 3), the cORR was 41.2% and the DCR was 82.0%. In the 12mg/kg Q3W subgroup (n=40), the cORR reached 55.0% and the DCR was 90.0%. In participants with HER2 1+ (n=27), the ORR reached 55.6% and the DCR was 88.9%. As of the data cutoff date, the median follow-up time was 11.9 months, and the median PFS was 7.1 months (95% CI: 5.2−10.8) in 12mg/kg Q3W dose group. The median OS was not mature with events in 14 (34.1%) pts and a 12-month OS rate of 63.9% (95% CI: 45.0−77.8).

Professor Qi Zhou, Chief Physician at the Gynecologic Oncology Center of Chongqing University Affiliated Cancer Hospital and the Principal Investigator of the gynecologic oncology cohort study, stated, “The treatment of platinum-resistant recurrent ovarian cancer is difficult and the prognosis is poor, threatening the life and health of women. Extending PFS and OS in platinum-resistant recurrent ovarian cancer patients remains a clinical challenge for gynecological oncologists. ADC drugs provide a new direction for overcoming resistance mechanisms by precisely delivering cytotoxic agents. HER2, as a validated solid tumor target, has made breakthroughs in breast and gastric cancer fields, while the novel ADC drug IBI354 shows broad-spectrum antitumor activity through unique design in HER2 low-expression (IHC 1+) platinum-resistant ovarian cancer. In the Phase 1 study with a dose of 12mg/kg Q3W, IBI354 demonstrated an ORR of 55.0% and DCR of 90.0%, with a median PFS reaching 7.1 months. The safety profile was very good without common severe interstitial lung disease or ocular toxicity seen in other ADCs. These results significantly outperform traditional chemotherapy regimens, suggesting its potential breakthrough efficacy in the platinum-resistant population. The Phase 3 study of IBI354 in platinum-resistant ovarian cancer (HeriCare-Ovarian01) has been initiated, and I am looking forward to the results, as well as the further validation of the long-term benefits for patients receiving IBI354.”

Doctor Charlotte Rose Lemech from Scientia Clinical Research Ltd, Australia, stated: “Breast cancer is one of the most common malignant tumors among women globally and remains a leading cause of cancer-related deaths. The amplification or overexpression of HER2 (human epidermal growth factor receptor 2) is recognized as a key driver in the development, progression, and metastasis of breast cancer, with approximately 15%-20% of breast cancer patients exhibiting HER2 overexpression. ADCs have become the new standard treatment for later line HER2 positive breast cancer. In this Phase 1 study, IBI354 has demonstrated encouraging efficacy and safety data, achieving high ORR and DCR especially in 9 mg/kg Q3W subgroup. Long term survival was also achieved with the median PFS of 14.1 months. IBI354 also differentiates itself from other HER2 targeted therapies with its safety profile. The incidence of interstitial lung disease was extremely low and most of the hematological toxicity and gastrointestinal adverse events were mild to moderate and can be effectively managed with standard supportive care. This favorable safety profile enhances the clinical application potential of IBI354 and we look forward to IBI354 achieving more breakthroughs in the field of breast cancer treatment.”

Dr. Hui Zhou, Senior Vice President of Innovent, stated: “With the rapid development of ADC drugs in the field of tumor treatment, Innovent is steadily advancing its strategic layout in the ADC field. At this year’s ASCO conference, we update the safety and efficacy data of IBI354 across various advanced solid tumors. These clinical results not only confirm the potential therapeutic value of IBI354 but also demonstrating Innovent’s innovative strength and technological advantages in ADC drug development. The phase 3 study of IBI354 in platinum-resistant ovarian cancer has been initiated, and more clinical studies are also planned. We will continue to invest in next-generation ADC molecules, aiming to address unmet clinical needs and bring patients with more effective and safer treatment options.”

About IBI354 (Anti-HER2 Antibody-Camptothecin Derivative Conjugate)

IBI354 is an innovative HER2-targeted antibody–camptocinin derivative conjugate developed by Innovent’s proprietary SoloTx ADC platform. With a drug-to-antibody ratio (DAR) of 8, IBI354 delivers a high payload of effective drugs to tumors. The highly hydrophilic linker design contributes to its excellent biophysical and pharmacokinetic (PK) properties, while the hydrophobic payload enhances its bystander effect, targeting adjacent antigen-low or negative tumor cells. IBI354 exhibits extremely low exposure of free toxin in circulation and has an ideal safety profile based on pre-clinical and clinical studies. IBI354 has demonstrated remarkable anti-tumor activity in various tumor-bearing mice models, particularly in those resistant to HER2-targeted therapies and in metastatic tumors. Innovent Biologics is conducting clinical studies to assess the efficacy and safety of IBI354 for multiple advanced solid tumors.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:

1Innovent does not recommend the use of any unapproved drug (s)/indication (s).

2Ramucirumab (Cyramza®) and Selpercatinib (Retsevmo®) and Pirtobrutinib (Jaypirca®) were developed by Eli Lilly and Company.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.